Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$74.52 – $218.25
51% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.9M | $50.1M | $56.8M | $67.9M | $93.5M | $124.9M | $161.5M | $212.9M |
| Cost of revenue | $220.0K | $1.4M | $355.0K | $21.2M | $465.0K | $32.5M | $301.0K | $309.0K |
| Gross profit | $35.7M | $48.7M | $56.4M | $46.7M | $92.9M | $92.4M | $161.2M | $212.6M |
| Gross margin | 105.4% | 97.2% | 99.3% | 68.7% | 99.4% | 74.0% | 99.8% | 99.9% |
| R&D | $4.8M | $5.9M | $6.8M | $6.4M | $6.5M | $7.1M | $7.7M | $6.2M |
| Operating income | $16.0M | $27.0M | $30.1M | $44.4M | $64.9M | $86.2M | $114.8M | $157.6M |
| EBITDA | $21.8M | $31.5M | $37.7M | $49.5M | $69.6M | $91.7M | $120.7M | $164.8M |
| Net income | $10.0M | $19.1M | $23.1M | $30.9M | $44.4M | $60.6M | $82.8M | $115.2M |
| Net margin | 29.4% | 38.2% | 40.6% | 45.4% | 47.6% | 48.6% | 51.3% | 54.1% |
| EPS (diluted) | 0.10 | 0.18 | 0.22 | 0.30 | 0.43 | 0.58 | 0.79 | 1.10 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $337M | $1.81 | $1.67–$1.97 | 1 |
| 2028 | $419M | $2.28 | $2.10–$2.47 | 1 |
| 2029 | $525M | $3.06 | $2.81–$3.32 | 1 |
| 2030 | $520M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
PRO MEDICUS LTD ORD
No one on the platform currently holds PMCUF.
No tracked institution reports a position in PMCUF as of their last filing.
No one on the platform has traded PMCUF yet.
| +0.00% |
| $12.1B |
| — |
| GIKLYGrifols, S.A. | $5.10 | +0.00% | $13.4B | — |
| IVBXFInnovent Biologics, Inc. | $11.03 | +7.36% | $19.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 127.5× earnings vs its 127.1× historical median P/E.
Fair value ≈ $147.49 · price $147.87 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.